Alison Kodjak
-
A quirk in the law gives an older opioid addiction treatment "orphan drug" status — and a period of exclusive market access. That may prevent some new therapies from reaching patients for years. -
The Trump administration wants to increase transparency in prescription drug pricing. But health economists say the administration's call to tie prices to what other nations pay might work better. -
Voters in Idaho, Utah and Nebraska approved ballot initiatives to expand Medicaid, overcoming roadblocks that had kept an estimated 300,000 people from obtaining coverage. -
Ballot initiatives in Utah, Nebraska and Idaho will determine whether to expand Medicaid, after legislators refused to do so. Montanans will vote on whether to keep the state's expansion intact. -
Though the federal government is changing its policy of separating immigrant children and parents, some children who were detained may suffer ongoing health consequences from the trauma. -
The Department of Health and Human Services is releasing more details of the President Trump's plan to reduce drug prices, including a new web site.
-
The federal funding of the program lapsed in September. States have been burning through leftover funds, or borrowing from other accounts, as they wait for Congress to act before the end of January. -
The U.S. government is scheduled to make large payments to health insurance companies to help offset discounts required by the Affordable Care Act. President Trump has threatened to stop the payments.
-
Most of the millions in the U.S. who are infected with hepatitis C can't afford the cure. Some say the U.S. could save money and cure more people if it bought the drugmaker Gilead Sciences Inc. -
EpiPen, the new poster child for prescription drug price gouging, may find that offering discount coupons isn't enough to mollify its critics in Congress and online.
